Acasti Pharma Inc. (NASDAQ: ACST) (TSX-V: ACST) stock plunged more than 22% in the premarketing today after the news that, since obtaining a subpoena from IIROC Company needs to clarify that it’s management and Board of Directors are unsure of any radical change in the company’s activities that will account for the sudden uptick in market activity.
The company has a monthly performance of 87.40%, compared to its half year performance of -28.09%. The biotech firm has 32 employees on its payroll and a Market capitalization of 41.66M. The price of the stock was trading -25.16% away from its 200-day simple moving average.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.